{'fraction_non_alphanumeric': 0.018218623481781375, 'fraction_numerical': 0.0020242914979757085, 'mean_word_length': 5.18125, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
T-lymphocytes and survival of head and neck squamous cell carcinoma.

The thymus-dependent lymphocytes (T cells) were enumerated in the peripheral circulation of 38 patients with histologically demonstrated squamous cell carcinoma of the head and neck. We have previously shown that this "total" T-cell count correlates well with degree of tumor involvement. A lower percentage of T cells were shown in patients with more advanced malignant neoplasms. Here we present follow-up data on these patients to evaluate the efficiency of the T-cell test in determining survival prognoses. We found no evidence that results of this test can extend prognostic abilities above those based on clinical staging. The survival data from six patients treated with a chemoimmunotherapy regimen of BCG vaccine, methotrexate sodium, and isoniazid did not demonstrate an increased survival time compared to patients at similar clinical stages who were treated by conventional use of surgery and irradiation.